1
|
Bhusal CK, Uti DE, Mukherjee D, Alqahtani T, Alqahtani S, Bhattacharya A, Akash S. Unveiling Nature's potential: Promising natural compounds in Parkinson's disease management. Parkinsonism Relat Disord 2023; 115:105799. [PMID: 37633805 DOI: 10.1016/j.parkreldis.2023.105799] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/05/2023] [Revised: 07/25/2023] [Accepted: 08/04/2023] [Indexed: 08/28/2023]
Abstract
Parkinson's disease (PD) is a common neurodegenerative disorder characterized by the progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta. Although the exact etiology of PD remains elusive, growing evidence suggests a complex interplay of genetic, environmental, and lifestyle factors in its development. Despite advances in pharmacological interventions, current treatments primarily focus on managing symptoms rather than altering the disease's underlying course. In recent years, natural phytocompounds have emerged as a promising avenue for PD management. Phytochemicals derived from plants, such as phenolic acids, flavones, phenols, flavonoids, polyphenols, saponins, terpenes, alkaloids, and amino acids, have been extensively studied for their potential neuroprotective effects. These bioactive compounds possess a wide range of therapeutic properties, including antioxidant, anti-inflammatory, anti-apoptotic, and anti-aggregation activities, which may counteract the neurodegenerative processes in PD. This comprehensive review delves into the pathophysiology of PD, with a specific focus on the roles of oxidative stress, mitochondrial dysfunction, and protein malfunction in disease pathogenesis. The review collates a wealth of evidence from preclinical studies and in vitro experiments, highlighting the potential of various phytochemicals in attenuating dopaminergic neuron degeneration, reducing α-synuclein aggregation, and modulating neuroinflammatory responses. Prominent among the natural compounds studied are curcumin, resveratrol, coenzyme Q10, and omega-3 fatty acids, which have demonstrated neuroprotective effects in experimental models of PD. Additionally, flavonoids like baicalein, luteolin, quercetin, and nobiletin, and alkaloids such as berberine and physostigmine, show promise in mitigating PD-associated pathologies. This review emphasizes the need for further research through controlled clinical trials to establish the safety and efficacy of these natural compounds in PD management. Although preclinical evidence is compelling, the translation of these findings into effective therapies for PD necessitates robust clinical investigation. Rigorous evaluation of pharmacokinetics, bioavailability, and potential drug interactions is imperative to pave the way for evidence-based treatment strategies. With the rising interest in natural alternatives and the potential for synergistic effects with conventional therapies, this review serves as a comprehensive resource for pharmaceutical industries, researchers, and clinicians seeking novel therapeutic approaches to combat PD. Harnessing the therapeutic potential of these natural phytocompounds may hold the key to improving the quality of life for PD patients and moving towards disease-modifying therapies in the future.
Collapse
Affiliation(s)
- Chandra Kanta Bhusal
- Post Graduate Institute of Medical and Research, Madhya Marg, Sector 12, Chandigarh, 160012, India.
| | - Daniel Ejim Uti
- Department of Biochemistry, Faculty of Basic Medical Sciences, College of Medicine, Federal University of Health Sciences, Otukpo, Benue State, Nigeria.
| | - Dattatreya Mukherjee
- Raiganj Government Medical College and Hospital, Uttar Dinajpur, West Bengal, India.
| | - Taha Alqahtani
- Department of Pharmacology, College of Pharmacy, King Khalid University, Abha, 62529, Saudi Arabia.
| | - Saud Alqahtani
- Department of Pharmacology, College of Pharmacy, King Khalid University, Abha, 62529, Saudi Arabia.
| | - Arghya Bhattacharya
- Department of Pharmacology, Calcutta Institute of Pharmaceutical Technology and Allied Health Science, Uluberia, Howrah, 711316, India.
| | - Shopnil Akash
- Faculty of Allied Health Science, Department of Pharmacy, Daffodil International University, Daffodil Smart City, Ashulia, Savar, Dhaka, 1207, Bangladesh.
| |
Collapse
|
2
|
Rogers DT, Pomerleau F, Kelley Z, Brown D, Lynn B, Gerhardt GA, Littleton J. Target-directed evolution of novel modulators of the dopamine transporter in Lobelia cardinalis hairy root cultures. J Biotechnol 2021; 342:28-35. [PMID: 34648893 DOI: 10.1016/j.jbiotec.2021.10.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2021] [Revised: 09/27/2021] [Accepted: 10/01/2021] [Indexed: 11/30/2022]
Abstract
The dopamine transporter (DAT) is targeted in substance use disorders (SUDs), and "non-classical"" DAT inhibitors with low abuse potential are therapeutic candidates. Lobinaline, from Lobelia cardinalis, is an atypical DAT inhibitor lead. Chemical synthesis of lobinaline is challenging; thus, "target-directed evolution" was used for lead optimization. A target protein is expressed in plant cells, and a mutant cell population is selected under conditions where target protein functional inhibition confers a survival advantage. Surviving mutants are "mined" for the targeted activity. Applied to a mutant L. cardinalis cell population expressing the human DAT, we identified 20 mutants overproducing DAT inhibitors. Microanalysis prioritized novel lobinaline derivatives, and we first investigated the more water-soluble lobinaline N-oxide. It inhibited rat synaptosomal [3H]DA uptake with an IC50 similar to lobinaline. Against repeated DA microinjections into the rat striatum, lobinaline produced transient DA clearance reductions. In contrast, lobinaline N-oxide prolongingly increased DA peak amplitudes, particularly in the ventral striatum. Lobinaline N-oxide also produced complex changes in post-peak DA clearance inconsistent with simple DAT inhibition. This unusual DAT interaction may prove therapeutically useful for treating SUDs. This study demonstrates the value of target-directed evolution of plant cells for optimizing lead compounds difficult to synthesize chemically.
Collapse
Affiliation(s)
- Dennis T Rogers
- Naprogenix™, UK-AsTeCC, 145 Graham Avenue, Lexington, KY 40506-0286, USA; College of Medicine, Department of Neurology, University of Kentucky Chandler Medical Center, 740 S. Limestone, Lexington, KY 40536-0298, USA.
| | - Francois Pomerleau
- College of Medicine, Department of Neuroscience, University of Kentucky Chandler Medical Center, 800 Rose St, Lexington, KY 40536-0298, USA; College of Medicine, Department of Neurology, University of Kentucky Chandler Medical Center, 740 S. Limestone, Lexington, KY 40536-0298, USA; College of Medicine, Brain Restoration Center, University of Kentucky Chandler Medical Center, 800 Rose St., Lexington, KY 40536-0298, USA; College of Medicine, Center for Microelectrode Technology, University of Kentucky Chandler Medical Center, 800 Rose St, Lexington, KY 40536-0298, USA
| | - Zachary Kelley
- Department of Chemistry, University of Kentucky, Lexington, KY 40536-9983, USA; College of Medicine, Department of Neurology, University of Kentucky Chandler Medical Center, 740 S. Limestone, Lexington, KY 40536-0298, USA
| | - Dustin Brown
- College of Medicine, Department of Neuroscience, University of Kentucky Chandler Medical Center, 800 Rose St, Lexington, KY 40536-0298, USA; College of Medicine, Department of Neurology, University of Kentucky Chandler Medical Center, 740 S. Limestone, Lexington, KY 40536-0298, USA
| | - Bert Lynn
- Department of Chemistry, University of Kentucky, Lexington, KY 40536-9983, USA; College of Medicine, Department of Neurology, University of Kentucky Chandler Medical Center, 740 S. Limestone, Lexington, KY 40536-0298, USA
| | - Greg A Gerhardt
- College of Medicine, Department of Neuroscience, University of Kentucky Chandler Medical Center, 800 Rose St, Lexington, KY 40536-0298, USA; College of Medicine, Department of Neurology, University of Kentucky Chandler Medical Center, 740 S. Limestone, Lexington, KY 40536-0298, USA; College of Medicine, Department of Psychiatry, University of Kentucky Chandler Medical Center, 245 Fountain Ct, Lexington, KY 40509, USA; College of Medicine, Department of Neurosurgery, University of Kentucky Chandler Medical Center, 800 Rose St, Lexington, KY 40536-0298, USA; College of Medicine, Brain Restoration Center, University of Kentucky Chandler Medical Center, 800 Rose St., Lexington, KY 40536-0298, USA; College of Medicine, Center for Microelectrode Technology, University of Kentucky Chandler Medical Center, 800 Rose St, Lexington, KY 40536-0298, USA
| | - John Littleton
- Naprogenix™, UK-AsTeCC, 145 Graham Avenue, Lexington, KY 40506-0286, USA; College of Medicine, Department of Neurology, University of Kentucky Chandler Medical Center, 740 S. Limestone, Lexington, KY 40536-0298, USA; College of Arts and Sciences, Department of Psychology, University of Kentucky, Kastle Hall, Lexington, KY 40506-0044, USA
| |
Collapse
|
3
|
Abstract
In this work, we reviewed the progress in the phytochemical and biological investigations of bioactive components derived from medicinally valuable Lobelia species. In the last 60 years, Lobelia has garnered significant attention from the phytochemist from around the world, majorly due to the discovery of bioactive piperidine alkaloids (e.g., lobinaline and lobeline) in the early 1950s. Later, lobeline underwent clinical trials for several indications including the treatment of attention deficit hyperactivity disorder and a multicenter phase three trial for smoking cessation. Subsequently, several other alkaloids derived from different species of Lobelia were also investigated for their pharmacological characteristics. However, in the last few years, the research focus has started shifting to the characterization of the other novel chemical classes. The major shift has been noticed due to the structurally similar alkaloid components, which essentially share similar pharmacological, physicochemical, and toxicological profiles. In this review, we present an up-to-date overview of their progress with special attention to understanding the molecular mechanisms of the novel bioactive components.
Collapse
Affiliation(s)
- Qinfang Zheng
- Hunan Academy of Chinese Medicine, Hunan University of Chinese Medicine, Changsha, China.,Key Laboratory of Dong Medical Research of Hunan Province, Hunan University of Medicine, Huaihua, China
| | - Ye Wang
- Key Laboratory of Dong Medical Research of Hunan Province, Hunan University of Medicine, Huaihua, China
| | - Shuihan Zhang
- Hunan Academy of Chinese Medicine, Hunan University of Chinese Medicine, Changsha, China.,2011 Collaboration and Innovation Center for Digital Chinese Medicine in Hunan, Changsha, China
| |
Collapse
|
4
|
Samdavid Thanapaul RJR, Ranjan A, Manikandan SK, Nadar MSAM. Efficacy of Lobelia alsinoides Lam ethanolic extract on a third-degree burn: An experimental study on rats. Dermatol Ther 2020; 33:e14242. [PMID: 32860351 DOI: 10.1111/dth.14242] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2020] [Revised: 08/11/2020] [Accepted: 08/21/2020] [Indexed: 02/02/2023]
Abstract
This is the first study to evaluate the topical application of Lobelia alsinoides Lam (LT) ethanolic extract on burns in rats. A deep third-degree burn wound was inflicted in adult male Wistar rats and the burns were dressed daily with a topical ointment formulation (Patent filed) comprising of Lobelia alsinoides Lam (5% and 10% w/w). The wound had noteworthy contraction and quicker eschar removal in 10% w/w LT-treated groups followed by 5% w/w treated groups on comparing with the commonly prescribed ointment (SilverexTM containing 1% w/w Silver sulfadiazine). Histopathological analysis showed that ointment containing 10% w/w LT ethanolic extract significantly increased fibroblast growth, which plays a major role in anatomic integrity, collagen synthesis, and accelerated the rate of the healing process. This study shows that the ethanolic extract of Lobelia alsinoides Lam, a previously pharmacologically unreported traditional medicinal plant, possesses wound contraction and eschar removal properties on burn wounds.
Collapse
Affiliation(s)
- Rex Jeya Rajkumar Samdavid Thanapaul
- Department of Surgery, Boston University School of Medicine, Boston, Massachusetts, USA.,Department of Biotechnology, Karunya Institute of Technology and Sciences (Deemed to be University), Coimbatore, Tamil Nadu, India
| | - Abraham Ranjan
- Department of Biotechnology, Karunya Institute of Technology and Sciences (Deemed to be University), Coimbatore, Tamil Nadu, India
| | - Sreeraj K Manikandan
- Department of Biotechnology, Karunya Institute of Technology and Sciences (Deemed to be University), Coimbatore, Tamil Nadu, India
| | - M S A Muthukumar Nadar
- Department of Biotechnology, Karunya Institute of Technology and Sciences (Deemed to be University), Coimbatore, Tamil Nadu, India
| |
Collapse
|
5
|
Khan MA, Wallace WT, Sambi J, Rogers DT, Littleton JM, Rankin SE, Knutson BL. Nanoharvesting of bioactive materials from living plant cultures using engineered silica nanoparticles. Mater Sci Eng C Mater Biol Appl 2020; 106:110190. [PMID: 31753369 PMCID: PMC6935263 DOI: 10.1016/j.msec.2019.110190] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/13/2018] [Revised: 09/09/2019] [Accepted: 09/10/2019] [Indexed: 12/25/2022]
Abstract
Plant secondary metabolites are valuable therapeutics not readily synthesized by traditional chemistry techniques. Although their enrichment in plant cell cultures is possible following advances in biotechnology, conventional methods of recovery are destructive to the tissues. Nanoharvesting, in which nanoparticles are designed to bind and carry biomolecules out of living cells, offers continuous production of metabolites from plant cultures. Here, nanoharvesting of polyphenolic flavonoids, model plant-derived therapeutics, enriched in Solidago nemoralis hairy root cultures, is performed using engineered mesoporous silica nanoparticles (MSNPs, 165 nm diameter and 950 m2/g surface area) functionalized with both titanium dioxide (TiO2, 425 mg/g particles) for coordination binding sites, and amines (NH2, 145 mg/g particles) to promote cellular internalization. Intracellular uptake and localization of the nanoparticles (in Murashige and Skoog media) in hairy roots were confirmed by tagging the particles with rhodamine B isothiocyanate, incubating the particles with hairy roots, and quenching bulk fluorescence using trypan blue. Nanoharvesting of biologically active flavonoids was demonstrated by observing increased antiradical activity (using 2,2-diphenyl-1-picrylhydrazyl radical scavenging assay) by nanoparticles after exposure to hairy roots (indicating general antioxidant activity), and by the displacement of the radio-ligand [3H]-methyllycaconitine from rat hippocampal nicotinic receptors by solutes recovered from nanoharvested particles (indicating pharmacological activity specific to S. nemoralis flavonoids). Post-nanoharvesting growth suggests that the roots are viable after nanoharvesting, and capable of continued flavonoid synthesis. These observations demonstrate the potential for using engineered nanostructured particles to facilitate continuous isolation of a broad range of biomolecules from living and functioning plant cultures.
Collapse
Affiliation(s)
- M Arif Khan
- Department of Chemical and Materials Engineering, University of Kentucky, Lexington, KY 40506, USA
| | - William T Wallace
- Department of Chemical and Materials Engineering, University of Kentucky, Lexington, KY 40506, USA
| | | | | | | | - Stephen E Rankin
- Department of Chemical and Materials Engineering, University of Kentucky, Lexington, KY 40506, USA.
| | - Barbara L Knutson
- Department of Chemical and Materials Engineering, University of Kentucky, Lexington, KY 40506, USA.
| |
Collapse
|
6
|
Kelley ZD, Rogers DT, Littleton JM, Lynn BC. Microfluidic capillary zone electrophoresis mass spectrometry analysis of alkaloids in Lobelia cardinalis transgenic and mutant plant cell cultures. Electrophoresis 2019; 40:2921-2928. [PMID: 31475363 PMCID: PMC7959097 DOI: 10.1002/elps.201900220] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2019] [Revised: 08/09/2019] [Accepted: 08/19/2019] [Indexed: 11/08/2022]
Abstract
Application of a microfluidic CE* device for CZE-MS allows for fast, rapid, and in-depth analysis of large sample sets. This microfluidic CZE-MS device, the 908 Devices ZipChip, involves minimal sample preparation and is ideal for small cation analytes, such as alkaloids. Here, we evaluated the microfluidic device for the analysis of alkaloids from Lobelia cardinalis hairy root cultures. Extracts from wild-type, transgenic, and selected mutant plant cultures were analyzed and data batch processed using the mass spectral processing software MZmine2 and the statistical software Prism 8. In total 139 features were detected as baseline resolved peaks via the MZmine2 software optimized for the electrophoretic separations. Statistically significant differences in the relative abundance of the primary alkaloid lobinaline (C27 H34 N2 ), along with several putative "lobinaline-like" molecules were observed utilizing this approach. Additionally, a method for performing both targeted and untargeted MS/MS experiments using the microfluidic device was developed and evaluated. Coupling data-processing software with CZE-MS data acquisition has enabled comprehensive metabolomic profiles from plant cell cultures to be constructed within a single working day.
Collapse
Affiliation(s)
- Zachary D Kelley
- Department of Chemistry, University of Kentucky, Lexington, KY, USA
| | | | - John M Littleton
- Department of Psychology, University of Kentucky, Lexington, KY, USA
- Naprogenix Inc., Lexington, KY, USA
| | - Bert C Lynn
- Department of Chemistry, University of Kentucky, Lexington, KY, USA
| |
Collapse
|
7
|
Macáková K, Afonso R, Saso L, Mladěnka P. The influence of alkaloids on oxidative stress and related signaling pathways. Free Radic Biol Med 2019; 134:429-444. [PMID: 30703480 DOI: 10.1016/j.freeradbiomed.2019.01.026] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/10/2018] [Revised: 01/16/2019] [Accepted: 01/21/2019] [Indexed: 12/19/2022]
Abstract
Alkaloids have always attracted scientific interest due to either their positive or negative effects on human beings. This review aims to summarize their antioxidant effects by both classical in vitro scavenging assay and at the cellular level. Since most in vitro studies used the DPPH (2,2-diphenyl-1-picrylhydrazyl) radical scavenging assay, the results from those studies are summed up in the first part of the article. In the second part, available data on the effect of alkaloids on NADPH-oxidase, the key enzyme for reactive oxygen species production, at the cellular level, are summarized. More than 130 alkaloids were tested by DPPH assay. However, due to methodological differences, a direct comparison is hardly possible. It can be at least concluded that some of them were either similar to or even more active than standard antioxidants and the number of aromatic hydroxyl groups seems to be the major determinant for the activity. The data on inhibition of NADPH-oxidase activity by alkaloids demonstrated that there is little relationship to the DPPH assay. The mechanism seems to be based on inhibition of synthesis, activation or translocation of NADPH-oxidase subunits. In some alkaloids, activation of the nuclear factor Nrf2 pathway was documented to be the grounds for inhibition of NADPH-oxidase. Interestingly, many alkaloids can behave both as anti-oxidants and pro-oxidants depending on conditions and pro-oxidation might be the reason for activation of Nrf2. Available data on other "antioxidant" transcription factors FOXOs and PPARs are also mentioned.
Collapse
Affiliation(s)
- Kateřina Macáková
- Department of Pharmaceutical Botany, Charles University, Faculty of Pharmacy in Hradec Králové, Heyrovského 1203, 500 05 Hradec Králové, Czech Republic.
| | - Rita Afonso
- Department of Pharmacology and Toxicology, Charles University, Faculty of Pharmacy in Hradec Králové, Heyrovského 1203, 500 05 Hradec Králové, Czech Republic.
| | - Luciano Saso
- Department of Physiology and Pharmacology "Vittorio Erspamer", Sapienza University of Rome, Piazzale Aldo Moro 5, Rome, Italy.
| | - Přemysl Mladěnka
- Department of Pharmacology and Toxicology, Charles University, Faculty of Pharmacy in Hradec Králové, Heyrovského 1203, 500 05 Hradec Králové, Czech Republic.
| |
Collapse
|
8
|
Folquitto DG, Swiech JND, Pereira CB, Bobek VB, Halila Possagno GC, Farago PV, Miguel MD, Duarte JL, Miguel OG. Biological activity, phytochemistry and traditional uses of genus Lobelia (Campanulaceae): A systematic review. Fitoterapia 2019; 134:23-38. [PMID: 30664918 DOI: 10.1016/j.fitote.2018.12.021] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2018] [Revised: 12/18/2018] [Accepted: 12/29/2018] [Indexed: 12/20/2022]
|
9
|
Abstract
Background: Native Americans have had a rich ethnobotanical heritage for treating diseases, ailments, and injuries. Cherokee traditional medicine has provided numerous aromatic and medicinal plants that not only were used by the Cherokee people, but were also adopted for use by European settlers in North America. Methods: The aim of this review was to examine the Cherokee ethnobotanical literature and the published phytochemical investigations on Cherokee medicinal plants and to correlate phytochemical constituents with traditional uses and biological activities. Results: Several Cherokee medicinal plants are still in use today as herbal medicines, including, for example, yarrow (Achillea millefolium), black cohosh (Cimicifuga racemosa), American ginseng (Panax quinquefolius), and blue skullcap (Scutellaria lateriflora). This review presents a summary of the traditional uses, phytochemical constituents, and biological activities of Cherokee aromatic and medicinal plants. Conclusions: The list is not complete, however, as there is still much work needed in phytochemical investigation and pharmacological evaluation of many traditional herbal medicines.
Collapse
Affiliation(s)
- William N Setzer
- Department of Chemistry, University of Alabama in Huntsville, Huntsville, AL 35899, USA.
- Aromatic Plant Research Center, 230 N 1200 E, Suite 102, Lehi, UT 84043, USA.
| |
Collapse
|
10
|
Brown DP, Rogers DT, Gunjan SK, Gerhardt GA, Littleton JM. Target-directed discovery and production of pharmaceuticals in transgenic mutant plant cells. J Biotechnol 2016; 238:9-14. [PMID: 27637316 PMCID: PMC5242497 DOI: 10.1016/j.jbiotec.2016.09.007] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2016] [Revised: 08/31/2016] [Accepted: 09/12/2016] [Indexed: 01/09/2023]
Abstract
Plants are a source of complex bioactive compounds, with value as pharmaceuticals, or leads for synthetic modification. Many of these secondary metabolites have evolved as defenses against competing organisms and their pharmaceutical value is "accidental", resulting from homology between target proteins in these competitors, and human molecular therapeutic targets. Here we show that it is possible to use mutation and selection of plant cells to re-direct their "evolution" toward metabolites that interact with the therapeutic target proteins themselves. This is achieved by expressing the human target protein in plant cells, and selecting mutants for survival based on the interaction of their metabolome with this target. This report describes the successful evolution of hairy root cultures of a Lobelia species toward increased biosynthesis of metabolites that inhibit the human dopamine transporter protein. Many of the resulting selected mutants are overproducing the active metabolite found in the wild-type plant, but others overproduce active metabolites that are not readily detectable in non-mutants. This technology can access the whole genomic capability of a plant species to biosynthesize metabolites with a specific target. It has potential value as a novel platform for plant drug discovery and production, or as a means of optimizing the therapeutic value of medicinal plant extracts.
Collapse
Key Words
- 1,2,3,6-tetrahydropyridine (MPTP)
- 1,2,3,6-tetrahydropyridine (MPTP: Pubmed CID: 1388)
- 1-methy-4-phenylpyridinium (MPP+: Pubmed CID: 39484)
- Activation tagging mutagenesis (ATM)
- Hairy root cultures
- Human dopamine transporter protein (hDAT)
- Lobelia cardinalis
- Lobinaline (1-Methyl-5,7-diphenyl-6-(3,4,5,6-tetrahydro-2-pyridinyl)decahydroquinoline (Pubmed CID: 419029)
- [(3)H]GBR12935 (Pubmed CID: 3455)
Collapse
Affiliation(s)
- D P Brown
- Department of Anatomy & Neurobiology, University of Kentucky, Lexington, KY, 40536-0298, USA
| | - D T Rogers
- Naprogenix Inc, University of Kentucky, AsTeCC, Lexington, KY 40506-0286, USA.
| | - S K Gunjan
- Department of Psychology, University of Kentucky, Lexington, KY, 40506-0044, USA
| | - G A Gerhardt
- Department of Anatomy & Neurobiology, University of Kentucky, Lexington, KY, 40536-0298, USA
| | - J M Littleton
- Naprogenix Inc, University of Kentucky, AsTeCC, Lexington, KY 40506-0286, USA; Department of Psychology, University of Kentucky, Lexington, KY, 40506-0044, USA
| |
Collapse
|